Want to see APLM full AI Analyst Report?
APLM Stock Chart & Stats
$22.52
-$0.28(-2.62%)
At close: 4:00 PM EST
$22.52
-$0.28(-2.62%)
Day’s Range― - ―
52-Week Range$3.66 - $42.12
Previous CloseN/A
Volume6.18K
Average Volume (3M)72.65K
Market Cap
$51.10M
Enterprise Value$12.77M
Total Cash (Recent Filing)$3.28M
Total Debt (Recent Filing)$643.00K
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.80
Shares Outstanding2,196,052
10 Day Avg. Volume95,090
30 Day Avg. Volume72,653
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-8.48
Price to Sales (P/S)3.18
P/FCF Ratio-2.61
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda4.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-122
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA large step-up in revenue demonstrates emerging commercial or partnership traction and a move beyond purely pre-revenue R&D. Sustainably growing revenue can lengthen runway, validate programs, and support future non-dilutive funding or commercial scale-up over the coming months if trends persist.
Modest LeverageLow absolute debt keeps interest and fixed financing obligations minimal, preserving flexibility for a clinical-stage biotech to prioritize R&D spending and strategic partnerships. Modest leverage reduces near-term solvency pressure and eases options for future capital raises or collaborations.
Improving Cash BurnA materially reduced cash burn versus the prior year indicates stronger cash management or revenue offsets to spending. Continued improvement in cash flow dynamics can extend runway, lower near-term financing needs, and reduce dilution risk if the trend remains over ensuing quarters.
Bears Say
Persistent Net LossesSustained operating and net losses mean the business must repeatedly access external capital to fund development. For a clinical-stage biotech, ongoing losses create structural financing risk, potential program prioritization, and dilution pressure that can persist over multiple funding cycles.
Negative EquityNegative shareholders' equity is a durable red flag that can limit financing options, increase perceived credit risk, and constrain strategic flexibility. It elevates the chance of distressed financings or onerous terms and complicates partner negotiations over the medium term.
Margin SustainabilityInconsistent or absent gross profit despite revenue growth suggests revenue may be non-recurring, low-margin, or tied to one-off milestones. That undermines durable path to profitability and makes it harder to rely on revenue to sustainably fund R&D and operating costs without persistent external financing.
Apollomics News
APLM FAQ
What was Apollomics’s price range in the past 12 months?
Apollomics lowest stock price was $3.66 and its highest was $42.12 in the past 12 months.
What is Apollomics’s market cap?
Apollomics’s market cap is $51.10M.
When is Apollomics’s upcoming earnings report date?
Apollomics’s upcoming earnings report date is Sep 24, 2026 which is in 68 days.
How were Apollomics’s earnings last quarter?
Apollomics released its earnings results on Apr 27, 2026. The company reported $3.795 earnings per share for the quarter, beating the consensus estimate of N/A by $3.795.
Is Apollomics overvalued?
According to Wall Street analysts Apollomics’s price is currently Overvalued.
Does Apollomics pay dividends?
Apollomics does not currently pay dividends.
What is Apollomics’s EPS estimate?
Apollomics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Apollomics have?
Apollomics has 2,196,052 shares outstanding.
What happened to Apollomics’s price movement after its last earnings report?
Apollomics reported an EPS of $3.795 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.693%.
Which hedge fund is a major shareholder of Apollomics?
Currently, no hedge funds are holding shares in APLM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apollomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.99%
12-Months-Change
Fundamentals
Return on Equity
288.40%
Trailing 12-Months
Asset Growth
-48.74%
Trailing 12-Months
Company Description
Apollomics
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Technical Analysis
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Exicure
―
CytoMed Therapeutics Limited
―
Ownership Overview
48.22% Insiders
0.03% Mutual Funds
― Other Institutional Investors
51.74% Public Companies and
Individual Investors